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We assessed the safety of guidewire-based measurement of coronary physiology, using intravenous adenosine,
in patients with an acute coronary syndrome.
Methods:Weprospectively enrolled invasivelymanaged STEMI and NSTEMI patients in two simultaneously con-
ducted studies in 6 centers (NCT01764334; NCT02072850). All of the participants underwent a diagnostic coro-
nary guidewire study using intravenous adenosine (140 μg/kg/min) infusion for 1–2 min. The patients were
prospectively assessed for the occurrence of serious adverse events (SAEs) and symptoms and invasively mea-
sured hemodynamics were also recorded.
Results: 648 patients (n= 298 STEMI patients in 1 hospital; mean time to reperfusion 253min; n= 350 NSTEMI
in 6 hospitals; median time to angiography from index chest pain episode 3 (2, 5) days) were included between
March 2011 andMay2013. TwoNSTEMI patients (0.03%overall) experienced a coronary dissection related to the
guidewire. No guidewire dissections occurred in the STEMI patients. Chest symptoms were reported in the ma-
jority (86%) of patient's symptoms during the adenosine infusion. No serious adverse events occurred during in-
fusion of adenosine and all of the symptoms resolved after the infusion ceased.
Conclusions: In this multicenter analysis, guidewire-based measurement of FFR and IMR using intravenous adenosine
was safe in patients following STEMI or NSTEMI. Self-limiting symptomswere common but not associatedwith serious
adverse events. Finally, coronary dissection in STEMI and NSTEMI patients was noted to be a rare phenomenon.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Coronary guidewire-based sensors can be used in the cardiac cathe-
terization laboratory to provide functional information on coronary ar-
tery disease severity and microvascular function. The myocardial
fractional ﬂow reserve (FFR) assesses the physiological signiﬁcance of
a coronary stenosis and is expressed as the ratio of maximal blood
ﬂow in a stenotic artery to maximal ﬂow if theoretically the artery
was unobstructed. FFR-guided management is evidence-based in pa-
tients with stable coronary artery disease (DEFER [1], FAME [2],nd Medical Sciences, University
land Ltd. This is an open access articlFAME-2 [3]) and has emerging clinical utility for measurement of non-
infarct artery disease in patients with recent or acute myocardial infarc-
tion (MI) [4,5]. The index of microvascular resistance (IMR) measured
in the culprit coronary artery has prognostic importance in patients
with acute ST-elevation myocardial infarction (STEMI) [6,7]. However
since FFR and IMR measurements involve pharmacological hyperemia
and guidewire instrumentation, there are theoretical risks of serious ad-
verse events (SAEs), including ventricular arrhythmias with intrave-
nous adenosine and coronary dissection (both ~0.5% incidence) [8].
Intravenous adenosine induces hyperemia through interactions with
A2A receptors. However, due to the ubiquitous expression of adenosine
receptors, adenosine is also associated with unwanted off-target side-
effects. For example, interaction with bronchial A2B receptors can lead
to mast cell degranulation and bronchoconstriction [9]. Furthermore,e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Clinical characteristics of the study participants on admission.
Characteristics STEMI
patients
n = 298
NSTEMI
patients
n = 350
Clinical
Age, years 59.4 62.0
Male sex, n (%) 216 (72) 260 (74)
BMI (kg/m2) 28.7 29 (5)
History
Hypertension, n (%) 95 (32) 159 (45)
Current smoking, n (%) 184 (62) 143 (41)
Hypercholesterolemia, n (%) 81 (27) 127 (36)
Diabetes mellitus ‡, n (%) 32 (11) 52 (15)
Previous myocardial infarction, n (%) 20 (7) 46 (13)
Previous PCI, n (%) 16 (5) 38 (11)
Presenting characteristics
Heart rate, bpm 80 (44) 74 (16)
Systolic blood pressure, mm Hg 135 (25) 141 (27)
Diastolic blood pressure, mm Hg 79 (14) 81 (17)
Time from symptom onset to reperfusion, min 253 –
Time from index episode of myocardial ischemia
to invasive angiogram, days
– 3 (2, 5)
Ventricular tachycardia or ﬁbrillation†, n (%) 20 (7) 0 (0)
Heart failure, Killip class at presentation, n (%) I 212 (71) 308 (88)
II 64 (22) 33 (9)
III 16 (5) 5 (2)
IV 6 (2) 4 (1)
Coronary angiography
Reperfusion strategy, n (%)
Primary PCI 275 (92) –
Rescue PCI (failed thrombolysis) 23 (8) –
Adjunctive therapy during PCI
Aspirin (%) 297 (99) 348 (99)
Clopidogrel (600 mg) (%) 297 (99) 337 (96)
Heparin (%) 298 (100) 333 (95)
Anti-GP IIb/IIIa (%) 273 (92) 79 (26)
Number of diseased arteries, n (%) 0 0 (0) 10 (3)
1 165 (55) 130 (37)
2 95 (32) 141 (40)
3 38 (13) 60 (17)
4 0 (0) 9 (3)
Culprit artery, n (%) LMS 0 (0) 2 (1)
LAD 110 (37) 152 (43)
LCX 55 (18) 106 (30)
RCA 133 (45) 90 (26)
TIMI coronary ﬂow grade pre-PCI, n (%) 0/1 214 (72) –
2 56 (19) –
3 28 (9) –
TIMI coronary ﬂow grade post-PCI, n (%) 0/1 2 (1) 33 (9)
2 14 (5) 27 (8)
3 282 (94) 289 (83)
Abbreviations: body mass index (BMI), percutaneous coronary intervention (PCI), beats
per minute (bpm), thrombolysis in myocardial infarction (TIMI), left main stem (LMS),
left anterior descending (LAD), left circumﬂex (LCX), right coronary artery (RCA).
‡ Diabetes mellitus was deﬁned as a history of diet-controlled or treated diabetes.
† VF or VT before or during PCI, but prior to adenosine infusion.
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negative chronotropic and dromotropic effects [10]. It is these unwanted
effects of adenosine that have motivated researchers to ﬁnd other drugs
for initiation of hyperemia or develop nonhyperemic indices of stenosis
assessment in the catheter laboratory [11,12].
Intracoronary adenosine may also be used therapeutically for the
treatment of no-reﬂow in STEMI [13,14], and the role of FFR-guided
PCI in STEMI patientswithmultivessel coronary disease [15] is currently
being evaluated in the COMPARE-ACUTE (NCT01399736), COMPLETE
(NCT01740479) and PRIMULTI (NCT01960933) clinical trials.
In November 2013 the United States (US) Food and Drug Adminis-
tration (FDA) issued a safety announcement on the risk of myocardial
infarction (MI) and death in patients receiving Adenoscan (adenosine)
for stress testing [16] (Supplementary File). This announcement follow-
ed from reports in the FDA Adverse Event Reporting System (FAERS)
and medical literature of serious adverse events (SAEs) from 1995 to
2013, including 6 cases of MI and 27 cases of death following adenosine
administration (typically within 6 h) [16].
We aimed to prospectively assess the safety of guidewire based
measurement of coronary physiology using intravenous adenosine
amongst patients with acute or recent myocardial infarction (MI).
Based on our prior experience with intravenous adenosine in this set-
ting [6,7,17,18], we hypothesized that intravenous adenosine would
be safe and well tolerated [19].
2. Methods
2.1. Study population
We simultaneously conducted two prospective studies involving assessments of coro-
nary physiology in patients with acute or recent MI. The ﬁrst was a study of the natural his-
tory of coronarymicrovascular function inpatientswith acute STEMI undergoing emergency
PCI (the BHF MR-MI study, NCT02072850) [20]. Two hundred and ninety-eight STEMI pa-
tients were enrolled acutely and had IMRmeasured invasively in the culprit coronary artery
with a diagnostic coronary guidewire (PressureWire Certus™, St Jude Medical) during pri-
mary or rescue PCI. The protocol did not involve FFR or IMR measurements in the non-
infarct arteries. The enrolment periodwasMarch 2011–November 2012. Patients diagnosed
with an acute STEMI [21] and who were undergoing primary or rescue PCI were eligible to
participate. In the second study, three hundred and ﬁfty NSTEMI patients were enrolled in
the BHF FAMOUS-NSTEMI study (NCT01764334) [4,5]. Six hospitals in the United
Kingdom participated (3 academic and 3 non-academic regional hospitals). The patients in
this study underwent urgent invasive management and had an FFR measurement in one
ormore coronary arteries with at least a single coronary stenosis ≥ 30% severity of the refer-
ence vessel diameter by visual assessment. The patients with NSTEMI were enrolled during
urgent care and the median time to invasive angiography was 3 days (Table 1) [5].
The exclusion criteria for administration of intravenous adenosine included evidence
of 2nd or 3rd degree heart block on the ECG, long QT syndrome, cardiogenic shock, or a
history of asthma concurrently treated with bronchodilators [22]. The exclusion criteria
for both studies are provided in Supplementary Tables 1 and 2. The study was approved
by the UKNational Research Ethics Service and all participants providedwritten informed
consent.
2.2. Catheter laboratory management
The clinical and catheter laboratory management followed contemporary guidelines
for STEMI [21] and NSTEMI [21,23].
2.3. Measurement of FFR and IMR
In patients with STEMI, infarct artery microvascular function (IMR) was measured at
the end of the primary or rescue PCI (Fig. 1). Thus we initially opted for a conventional
workhorse wire while using a pressure wire at the end of the procedure. In patients
with NSTEMI, FFR (and IMR) was measured at the beginning of the diagnostic procedure
in all participants. Additionally, the pressurewirewas used to performPCI inmost NSTEMI
patients. FFR and IMR were measured using a temperature and pressure sensitive guide
wire (PressureWire Certus™ St Jude Medical, Uppsala, Sweden). The guidewire was cali-
brated outside the body, equalizedwith aortic pressure at the ostiumof the guide catheter,
and then advanced to the distal third of the culprit artery [6,7,17,18]. Intracoronary nitrate
(200 μg) was administered to minimize coronary artery tone and maintain coronary vol-
ume. Intravenous adenosine was administered at a rate of 140 μg/kg/min via a large pe-
ripheral vein for 1–2 min (Supplementary Table 3).
The patient's response to adenosine administration was a pre-deﬁned safety outcome
[20]. Aortic and distal coronary pressures were recorded invasively before and during aden-
osine administration. In addition, patients' symptoms andheart rate during the adenosine in-
fusion were also prospectively documented using a study proforma. All SAEs in studyparticipants were prospectively documented by clinical and research staff after the patient
was enrolled in the study in line with the trial protocol. All adverse events were recorded
in the clinical report form (CRF). SAEs were notiﬁed to the Sponsor of the studies for
pharmacovigilance and assessed, reported, analyzed and managed in accordance with the
Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended) [24].
An SAE was deﬁned as an event that results in death, is life threatening, requires
hospitalization or prolongation of existing hospitalization, results in persistent or
signiﬁcant disability or incapacity, or is otherwise considered medically signiﬁcant by the
investigator.
Major adverse cardiac events (MACE), were deﬁned as the occurrence of death, myo-
cardial infarction, or hospitalization for heart failure [25]. In the STEMI study, source data
for all of the SAE andMACE were assessed by a cardiologist (A.M.) who was independent
of the research team. This cardiologist was blinded to all of the other clinical data [20].
In the NSTEMI study, source clinical data for all SAEs of suspected cardiovascular or-
igin and all deaths were reviewed by an independent clinical event committee
blinded to treatment group assignment (FFR-guided group or angiography guided
group) [4,5]. The CEC also assessed the angiograms of SAE attributed to procedure-
related complications.
Fig. 1. A hemodynamic recording obtained from a diagnostic pressure- and temperature-sensitive guidewire (PressureWire Certus™, St. Jude Medical, Mn.) located in a culprit coronary
artery at the end of primary PCI. The blue arrow represents the thermodilution recordings during resting conditions before adenosine administration. The thermodilution curve represents
the transit time for the change in temperature detected by the distal guidewire thermistor following intra-coronary bolus injection of saline (room temperature) via the guiding catheter.
The subsequent yellow arrow represents the transit times for thermodilution curves following intra-coronary injections of saline during hyperemiawith adenosine (140 μg/kg/min). Dur-
ing hyperemia, there is evidence of a reduction in arterial blood pressure depicted by the yellow arrow, reﬂecting the typical hemodynamic response in the systemic and coronary circu-
lations to intravenous adenosine. Hemodynamic recordings were assessed with vendor software (RADIView Version 2.2, St Jude Medical, Mn.). The systolic blood pressure and diastolic
blood pressure during at least 3 cardiac cycles in steady-state conditions at rest and during hyperemiawere assessed. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
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Continuous data with a normal distribution were summarized with the mean ±
standard deviation (SD). Paired t-tests were used to assess hemodynamic data before
and during adenosine administration. Signiﬁcance was deﬁned as a p value b 0.05.
The statistical analyses were performed using the SPSS statistical software package
14.0 for Windows (SPSS Inc., Chicago, IL, USA).3. Results
3.1. Baseline characteristics
648 patients (n = 298 patients with STEMI in 1 hospital; n = 350
patients with NSTEMI in 6 hospitals) were included between March
2011–May 2013. Their clinical characteristics are presented in Table 1.
In the patients with STEMI, evidence of hemodynamic instability on
arrival in the cardiac catheter laboratory was common. Thirty-three
(11.1%) patients had a systolic blood pressure (BP) of b90 mm Hg, 20
(7.2%) patients had ventricular ﬁbrillation (VF) or ventricular tachycar-
dia (VT) before or during PCI but prior to adenosine administration,
and 4 (1.4%) patients received intra-aortic balloon pump (IABP)
counterpulsation therapy during the PCI. In the patients with NSTEMI
there were no patients with VF/VT during the procedure and only 1
(0.3%) patient required IABP.
3.2. Symptoms and adverse events
During adenosine infusion, 255 (85.6%) STEMI patients reported
symptoms including chest discomfort, dyspnea and facial ﬂushing, all
of which resolved immediately after the infusion ceased. There were
no other symptoms reported. No MACE, atrial or ventriculararrhythmias occurred in association with intravenous adenosine ad-
ministration. There were no SAEs related to adenosine.
In the STEMI cohort, MACE occurred in 3 (1.0%) patients within 24 h
of the PCI. One patient experienced an acute stent thrombosis associat-
ed with a dissection at the distal end of the stent; one patient with se-
vere left ventricular dysfunction experienced ventricular ﬁbrillation in
the coronary care unit; one patient died suddenly frommyocardial rup-
ture that was conﬁrmed at autopsy. All of these events occurred in the
coronary care unit and none of these events were temporally associated
with the adenosine infusion in the catheter laboratory. In the STEMI co-
hort therewere no pressure-wire related dissections and no SAE related
to arrhythmias.
In the NSTEMI cohort, no MACE occurred in association with the
adenosine infusion. There were 2 (0.6%) cases of coronary dissection re-
lated to the guidewire. Therewere 4 cases of in-hospital adverse events,
including 3 (0.9%) cases of contrast nephropathy and 3 (0.9%) cases of
major bleeding but none related to adenosine infusion. There were no
SAE related to bradyarrhythmias or tachyarrhythmias and FFR was
measured in all subjects.
3.3. Hemodynamic changes
3.3.1. All patients
In 330 patients with complete hemodynamic data (n = 186 STEMI,
n = 144 NSTEMI), aortic systolic blood pressure was reduced during
adenosine administration (systolic BP (rest vs. adenosine): 124.5
(26.0) mm Hg vs. 111.7 (24.7) mm Hg (n = 330) ([95% CI 12.8 (11.3,
14.3) p b 0.001]) as was diastolic BP (67.0 (12.8) mm Hg vs. 60.5 (13.2)
mmHg (n=330) ([95% CI 6.5 (5.6, 7.4) p b 0.001]). Heart rate increased
to 64.7 (13.0) bpm from 58.3 (12.1) bpm [95% CI 6.3 (5.6, 7.1) p b 0.001].
The proximal aortic pressure (Pa) was also reduced during adenosine
Table 3
Coronary (Pd) systolic and diastolic blood pressure recorded in 258 STEMI subjects.
Blood pressure (BP) Rest Adenosine Mean change (CI) p value
Mean systolic (SD)
mm Hg
114.6 (22.6) 98.8 (21.8)* 15.8 (14.1, 17.5) b0.001
Mean diastolic (SD)
mm Hg
65.5 (13.9) 56.1 (14.4)* 9.4 (8.4, 10.3) b0.001
Abbreviations: blood pressure (BP), standard deviation (SD), *p b 0.001 vs. baseline
(paired t-test).
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104.2 (25.0) mm Hg (n = 351) ([95% CI 15.5 (13.9, 17.0) p b 0.001]) as
was the distal coronary pressure (64.7 (14.4) mm Hg vs. 55.2 (14.4)
mm Hg ([95% CI 9.4 (8.5, 10.4) p b 0.001]).
3.3.2. STEMI
In the STEMI cohort (n = 298), non-invasive hemodynamic data
(blood pressure and heart rate) were available for all study partici-
pants (Table 2). Complete aortic hemodynamic data before and dur-
ing adenosine infusion were available in 186 STEMI patients with
distal coronary (Pd) hemodynamic data recorded in 258 STEMI pa-
tients (Table 3). The mean (SD) aortic systolic BP fell from 120.0
(22.6) mm Hg at baseline to 106.5 (21.3) mm Hg during adenosine
infusion [95% CI 13.5 (11.6, 15.5) p b 0.001]. Aortic diastolic BP was
also reduced by adenosine infusion (67.9 (13.5) mm Hg vs. 61.0
(13.6) mmHg) [95% CI 7.0 (5.8, 8.1) p b 0.001] whereas heart rate in-
creased from 63.2 (12.1) bpm at rest to 69.8 (12.5) bpm [95% CI 6.6
(5.6, 7.6) p b 0.001]. Compared to patients who did not experience
symptoms with adenosine, patients who did experience symptoms
had a greater rise in heart rate, but BP changes were similar (Table 4).
3.3.3. NSTEMI
In the NSTEMI cohort (n = 350), complete aortic hemodynamic
data were available for 144 NSTEMI patients with distal coronary
(Pd) hemodynamic data recorded in 165 NSTEMI patients. The
mean (SD) non-invasive aortic systolic BP reduced from 130.3
(28.8) mm Hg under resting conditions to 118.5 (27.0) mm Hg dur-
ing adenosine infusion [95% CI 11.8 (9.4, 14.2) p b 0.001]. Aortic dia-
stolic BP was also reduced by adenosine infusion (65.9 (11.9) mmHg
vs. 60.0 (12.7) mmHg [95% CI 5.9 (4.5, 7.2) p b 0.001]). Heart rate in-
creased to 58.1 (11.0) bpm from 52.1 (8.8) bpm (n = 144) [95% CI
6.0 (4.8, 7.2) p b 0.001] and distal coronary (Pd) pressure was re-
duced also (Table 5).
4. Discussion
We report the largest study to date of guidewire-based measure-
ments of FFR and/or IMR in patients with acute coronary syndromes.
Our study is the ﬁrst to report information on a pre-speciﬁed outcome
relating to the safety of intravenous adenosine in patients with an
acute STEMI or recent NSTEMI, whowere prospectively enrolled simul-
taneously in parallel studies. Themain ﬁndings of ourmulticenter study
are that, ﬁrst, coronary dissection due to the guidewire was rare
(≤0.03%). Second, brief intravenous adenosine infusion in MI patients
for diagnostic purposes was commonly associated with symptoms but
these symptoms were brief and self-limiting and were not associated
with any SAEs; most importantly, the use of adenosine was safe and
not associated with any SAEs during routine emergency care.
Only 2 guidewire-related coronary dissections occurred in 698 pro-
spectively enrolled MI patients undergoing emergency or urgent inva-
sive management. This result represents evidence for the safety of
guidewire-based assessments of coronary physiology. Guidewire dis-
sections were less common than in previous studies [e.g., RIPCORD
(1.5%)] [8].We believe that the timing of the pressurewire studywithinTable 2
Blood pressure and heart rate at the start and end of emergency PCI in 298 STEMI subjects.
Parameter PCI start PCI end Mean Change (CI) p value
Mean heart rate
(SD) bpm
80.1 (44.1) 79.5 (14.5) 0.6 (−4.3, 5.6) 0.800
Mean systolic BP
(SD) mm Hg
135.1 (24.7) 121.0 (21.1)* 14.0 (11.6, 16.4) b0.001
Mean diastolic BP
(SD) mm Hg
79.0 (13.9) 71.9 (12.9)* 7.0 (5.6, 8.5) b0.001
Abbreviations: heart rate (HR), blood pressure (BP), standard deviation (SD), *p b 0.001
vs. baseline (paired t-test).the procedure partially explains the difference in the dissection rates. In
the patients with acute STEMI, pressure wire instrumentation in the
infarct-artery post-PCI was not associated with any complications. In
the patients with recent NSTEMI, the 2 guidewire dissections occurred
during diagnostic procedures before stent implantation. In the 350
NSTEMI participants in this trial, 706 lesions (≥30% lumen narrowing)
were reported and FFR data were obtained in 704 (N99%) of these le-
sions. On average 2 arteries per patient were instrumented with a pres-
sure wire. Despite this, the incidence of guidewire dissections in the
NSTEMI patients was very low and this experience is evidence of safety
in the hands of trained cardiologists.
In our study, predictable symptoms associated with intravenous
adenosine occurred in the majority of patients and can be explained
by the pharmacological effects of this naturally occurring vasodilator
[25]. However, since the half life of adenosine is b 10 s, these symptoms
were extremely short-lived [26]. Patients who experienced symptoms
had a slightly higher increase in heart rate. A minority of patients
(14%) did not experience symptoms with adenosine infusion. This
may be explained by the presence of concurrent chest symptoms asso-
ciated with myocardial infarction and also treatment with sedative and
opiate therapies. There were no serious adverse events associated with
intravenous adenosine. None of the patients experienced sustained atri-
al or ventricular tachyarrhythmia. Overall, the reported symptoms that
were observed in these cohorts were typical of what might be expected
with intravenous adenosine. Based on the evidence of safety in this
study, we think that when a clinician plans to administer intravenous
adenosine, the patient should be advised that symptoms are likely but
self-limiting and not associated with any other consequences. Adverse
events, such as atrial and ventricular ﬁbrillation, are rare [8] and, in
fact, no such events occurred in the 648 MI patients in this analysis.
Systolic and diastolic blood pressures were reduced with intrave-
nous adenosine consistent with an A2A receptor-mediated response.
However, a rise in heart rate of N10% or a fall in systolic BP N10% oc-
curred in less than half of the STEMI and NSTEMI patients in our
study. These observations could be explained by the fact that the pa-
tients already had tachycardia due to STEMI, and they had been treated
with vasoactive drugs, which attenuate the systemic reﬂex sympatho-
excitation response (e.g., intravenous morphine). It is also possible
that there was an attenuated sympathetic response due to beta blocker
treatment.
Of the 6 hospitals in the FAMOUS-NSTEMI trial [4,5], 3 were regional
non-academic centerswithout a track record in coronary physiology re-
search. The multicenter design was intended to make the results of this
trial more representative of routine care, relevant to “real world” prac-
tice and novel.
In STEMI patients, guidewire-based measurement of coronary mi-
crovascular function with intravenous adenosine is mainly used in clin-
ical research studies (as was the case here in the STEMI group). IMR in
the infarct-related artery has prognostic value when measured
invasively at the end of primary PCI [6,7,17,18], and IMR has potential
utility for stratiﬁcation of higher risk patients for more intensive man-
agement after primary PCI [6,18]. Moreover, potential diagnostic appli-
cations are emerging for FFR to inform the acute treatment decisions for
patients with non-infarct artery disease [5]. Intracoronary adenosine is
used to treat no-reﬂow [13,14] and FFR-guided PCI in STEMI patients
Table 4
Blood pressure and heart rate of STEMI patients with symptoms recorded (n = 186) and who reported symptoms vs. no symptoms.
Parameter Symptoms
(n = 154)
No symptoms
(n = 32)
Mean difference (CI) p value
Mean (SD) systolic change, mm Hg −14.2 (13.5) −10.5 (13.5) −3.6 (−8.3, 1.5) 0.167
Mean (SD) diastolic change, mm Hg −7.2 (7.8) −6.0 (8.4) −1.2 (−4.2, 1.9) 0.451
Mean (SD) HR change, bpm 7.1 (7.0) 4.0 (6.2)* 3.1 (0.5, 5.7) 0.020
Abbreviations: heart rate (HR), standard deviation (SD), *p b 0.05 vs. baseline (unpaired t-test).
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the COMPARE-ACUTE (NCT01399736), COMPLETE (NCT01740479)
and PRIMULTI (NCT01960933) trials.
In our study invasivemeasurements of FFR and IMR can be safely ob-
tained in patients with acute or recent MI. IMR has been shown to be a
biomarker of severe microvascular injury and has prognostic value in
identifying the highest risk patients at an early stage, potentially en-
abling triage of higher risk patients to intensiﬁcation of therapy. FFR
measurement in the acute setting, especially in non-culprit disease,
has much promise and is undergoing ongoing evaluation in clinical
trials.
Adenosine is an established drug for use in pharmacological stress
testing. Adenoscan has been marketed from 18 May 1995. From this
date until 10 April 10 2013 the FAERS database accrued 26 reports of
myocardial infarction (MI) and 29 deaths with regadenoson and 6 re-
ports of myocardial infarction and 27 deaths reported with Adenoscan.
There were two case reports of MI associated with Lexiscan administra-
tion but nonewith Adenoscan [27,28] and the incidence of cardiovascu-
lar adverse events associated with these drugs is similarly uncommon
[29–33]. In light of these post-marketing reports the FDA recommended
to “Avoid using these drugs (Lexiscan or Adenoscan) in patients with signs
or symptoms of unstable angina or cardiovascular instability, as these pa-
tients may be at greater risk for serious cardiovascular adverse reactions”
[16]. The FDAwarningwas directed to ofﬁce-based administration of in-
travenous adenosine, and this environment contrasts with the cardiac
catheterization laboratory where medical support is immediately avail-
able to treat patientswith iatrogenic complications. Our results alsopro-
vide reassurance for the use of intravenous adenosine in the catheter
laboratory setting.
In contrast to the FDA recommendations, our ﬁndings are supported
by the results from similar studies in other centers, in which intravenous
adenosine has been used in patients with acute MI [7,34–37,35]. More-
over, a meta-analysis evaluating the safety and efﬁcacy of intracoronary
adenosine in 460 patients with STEMI undergoing PCI found no differ-
ence in the safety endpoints of bradycardia, ventricular arrhythmia and
chest pain compared with placebo [38]. Our study is different, since the
safety of diagnostic guidewire instrumentation and systemic administra-
tion of adenosine (rather than intracoronary adenosine) were prospec-
tively assessed in NSTEMI and STEMI patients. Another study, using a
similar protocol for adenosine, demonstrated all patients tolerated aden-
osine infusion, with no episodes of clinically signiﬁcant bradycardia [34].
In our hands, adenosine was not associated with any SAEwhen adminis-
tered to reperfused patientswith STEMI at the end of emergency PCI for a
short period of time (1–2min) and the absence of SAE in the NSTEMI pa-
tients provides further evidence of safety.Table 5
Distal coronary (Pd) artery blood pressure recorded in 165 NSTEMI subjects.
Blood pressure (BP) Rest Adenosine Mean change (CI) p value
Mean systolic (SD)
mm Hg
125.7 (28.3) 110.4 (26.4)* 15.3 (13.0, 17.7) b0.001
Mean diastolic (SD)
mm Hg
63.7 (14.2) 53.7 (13.7)* 10.0 (8.4, 11.5) b0.001
Abbreviations: blood pressure (BP), standard deviation (SD), *p b 0.001 vs. baseline
(paired t-test).5. Limitations
Our study has several limitations. First, we do not have information
on other hyperemic drugs, such as regadenoson. Second, although safe-
ty assessmentswere performed and recorded in all of the patients at the
time of the procedure, symptom reporting was incomplete. The avail-
able results conﬁrm that symptoms typically occur with intravenous
adenosine. Third, complete hemodynamic recordings were not avail-
able in all of the participants because resting arterial pressure is not re-
quired for IMR. Fourth, pressure wire studies were restricted to the
infarct-related artery rather than the non-infarct artery in the STEMI co-
hort study. Nonetheless, we provide comprehensive hemodynamic data
and information on symptoms from prospective evaluations in individ-
ual patients who were enrolled in studies that had been designed with
an open approach to enrolment of ‘all-comers’. We think our observa-
tions are representative of ‘real-world’ clinical practice.
6. Conclusion
Guidewire-based measurement of coronary microvascular function
involving intravenous adenosine infusion was feasible and safe during
emergency or urgent PCI for STEMI and NSTEMI. The symptoms related
to adenosine were predictable, self-limiting and not associatedwith ad-
verse events. Finally, coronary dissection inMI patients was noted to be
a rare phenomenon.
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